According to a new report, published by KBV research, The Global Non Hodgkin Lymphoma Therapeutics Market size is expected to reach $16.8 billion by 2030, rising at a market growth of 8.4 % CAGR during the forecast period.
The B-Cell Lymphoma segment is leading the Global Non Hodgkin Lymphoma Therapeutics Market by Cell Type in 2022; thereby, achieving a market value of $10.9 billion by 2030. Drugs like rituximab and obinutuzumab specifically target B-cell markers, such as CD20, on the surface of B cells. They are often used in combination with chemotherapy to enhance treatment effectiveness. Drugs like pembrolizumab and nivolumab, which target immune checkpoint proteins, have shown efficacy in some B-cell lymphomas. They work by unleashing the immune system to attack cancer cells. Drugs like ibrutinib and acalabrutinib target Bruton's tyrosine kinase (BTK) pathway, which is crucial for B-cell survival.
The Chemotherapy segment is experiencing a CAGR of 9.2% during (2023 - 2030). The Targeted Therapy market would register a CAGR of 8.7% during (2023 - 2030). Chemotherapy is often combined with other modalities, such as immunotherapy or targeted therapies. Combinatorial approaches enhance treatment efficacy and provide synergistic effects, improving outcomes and expanding the available therapeutic options. Chemotherapy is often used as part of conditioning regimens before hematopoietic stem cell transplantation (HSCT) in certain NHL cases. The expansion of HSCT procedures, coupled with the use of chemotherapy, contributes to the growth of NHL therapeutics, particularly in cases where transplant is a viable option.
Full Report: https://www.kbvresearch.com/non-hodgkin-lymphoma-therapeutics-market/
The North America region dominated the Global Non Hodgkin Lymphoma Therapeutics Market by Region in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $6.5 billion by 2030. The Europe region is anticipating a CAGR of 8% during (2023 - 2030). Additionally, The Asia Pacific region would exhibit a CAGR of 9.3% during (2023 - 2030).
By Cell Type
By Therapy Type
Unique Offerings 
